Abstract:In the proposed intelligent biosensing drug‐induced cardiotoxicity assessment platform, the cardiomyocytes are treated with non‐cardiotoxic or cardiotoxic drugs to obtain mechanical beating signals. The beating signals are converted into image representations by phase space reconstruction and analyzed by convolutional neural network to identify the cardiotoxicity of drugs. Drug‐induced cardiotoxicity often leads to patient deaths and drug recalls. Interdigitated electrode (IDE)‐based cellular impedance detection instrument has been integrated with intelligent algorithms to screen cardiotoxicity based on cardiomyocytes. These intelligent biosensing systems generally employ traditional machine learning methods to assess drug‐induced cardiotoxicity by analyzing cardiomyocytes mechanical beating signals. However, modern deep learning methods with robustness and flexibility have not been integrated in IDE‐based platform to screen cardiotoxicity. Here, for the first time, we implemented deep convolutional neural network (CNN) to analyze cardiomyocytes mechanical beating signals for cardiotoxicity assessment. This method can eliminate the feature engineering procedures, such as manual design and extraction of signal features required by traditional machine learning methods. To facilitate two‐dimensional (2‐D) CNN analysis, we utilized phase space reconstruction to convert one‐dimensional beating signals into 2‐D image representations as well as take into account nonlinear dynamic information. The phase space reconstruction‐assisted convolutional neural network (PSRCNN) is capable of accurately categorizing drug‐induced cardiotoxicities and predicting cardiotoxicity levels. It obtains accuracies ranging from 0.82 to 0.99 when recognizing the cardiotoxicity of newly developed drugs, which are represented by drugs that are not used during model training. Furthermore, we explore in depth to compare the performance of CNN with other traditional machine learning methods. The PSRCNN method can achieve higher accuracies when compared to other methods. The PSRCNN‐based biosensing platform is highly potential in improving the efficiency and accuracy of high‐throughput screening of newly developed drugs for cardiotoxicity during drug discovery.

Cardiotoxicity Assessment through a Polymer‐Based Cantilever Platform: An Integrated Electro‐Mechanical Screening Approach

Cardiotoxicity Assessment through a Polymer‐Based Cantilever Platform: An Integrated Electro‐Mechanical Screening Approach (Small 33/2024)

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform

Multifunctional cardiac microphysiological system based on transparent ITO electrodes for simultaneous optical measurement and electrical signal monitoring

High-temporal-range Drug-Induced Cardiac Side-Effect Evaluation Using Simultaneous HL-1-based Impedance and Long-Term Electrophysiology Recording Systems

Cardiotoxicity screening: a review of rapid-throughput in vitro approaches

Beating Cardiac Cell-Based Biosensor and Its Application in Drugs Screening

A Comprehensive Cardiotoxicity Assay by Combining High-Throughput Multiple Ion Channel Screening with Human Cardiomyocyte-Based Action Potential Validation

Electromechanical Integrated Recording of Single Cardiomyocyte in Situ by Multimodal Microelectrode Biosensing System.

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Contractility measurements for cardiotoxicity screening with ventricular myocardial slices of pigs

An intelligent biosensing platform using phase space reconstruction‐assisted convolutional neural network for drug‐induced cardiotoxicity assessment

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.

Biohybrid 3D Printing of a Tissue‐Sensor Platform for Wireless, Real‐Time, and Continuous Monitoring of Drug‐Induced Cardiotoxicity

Real-time electro-mechanical profiling of dynamically beating human cardiac organoids by coupling resistive skins with microelectrode arrays

Universal and Sensitive Drug Assessment Biosensing Platform Using Optimal Mechanical Beating Detection of Single Cardiomyocyte

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays